CD274 and cancer: According to recent studies, immunotherapy has made comparable progress in cancer treatment (Ohaegbulam et al., 2015), and our findings also suggest that some people with higher immunological ratings may benefit from PD-L1 inhibitor therapy (Zhong et al., 2020; Liu et al., 2021).